Projects Blog Leitat’s Post

Exciting news from Vilnius University Life Sciences Center! 🧬 Dr. Patrick Pausch and his team have been awarded a prestigious European Research Council (ERC) Starting Grant. This funding will support their cutting-edge research on jumbo phages, a fascinating class of large viruses that infect bacteria. The project, titled "Jumbo Phages in Translational Enzyme Research" (JUPITER), aims to uncover the hidden potential of jumbo phage genes, which may lead to significant advancements in biotechnology. With their genomes up to ten times larger than typical phages, jumbo phages hold untapped resources that could inspire new antimicrobial strategies and genome-editing tools for a variety of applications—from combating drug-resistant bacteria to improving agricultural crops. We're proud to see Lithuania and Vilnius University Life Sciences Center at the forefront of this exciting research! Learn more about this groundbreaking project here: https://lnkd.in/d9NjH36v #vilniusuniversity #lifesciencescenter #jumbophages #ERCGrant #JUPITER

Serbia, New Bioeconomy Hub In Europe “I think the biggest innovations of the twenty-first century will be the intersection of biology and technology. A NEW ERA IS BEGINING, JUST LIKE THE DIGITAL ONE.” Steve Jobs, 2011 #BIO4Kampus #bio4campus #bioeconomy #bioeconomyHUB

BIO4 Campus in Belgrade is opened for future tenants. Details are in the link below. This is one more example of how strong Serbia's position is in bioeconomy and innovative technologies. #bio4campus #bioeconomy #serbia

🚨 Big Win for Opera Bioscience 🚨 We just landed a Phase I SBIR grant from the NIH. This is an important milestone and a huge statement of support. Our tech is here to make protein production cheaper and easier, and this grant is the fuel we need to push even harder. Shoutout to the relentless crew who've put in the hard work to get us to where we are, and to the National Institute of General Medical Sciences for backing bold science. We're just getting things started—expect more breakthroughs as we're here to change-up the decades old processes holding biomanufacturing back. #SBIR #NIHGrant #BiotechInnovation #ProteinExpression #RecombinantProteins #Biotechnology #OperaBioscience #BiotechRebellion

If you're going to be at BIO this week, check out the NSCEB sessions below!

The future of human longevity is being written in the labs of organizations like SENS Research Foundation. Brilliant scientists like Dr. Amutha Boominathan, Senior Investigator I, MitoSENS, combine cutting-edge biotechnology with visionary thinking to tackle age-related diseases head-on. Their work isn't just advancing science—it's reimagining overall health. What breakthroughs do you think will define the next decade of longevity research? Learn more about our team: https://ow.ly/2c6I50SNwUL #LongevityResearch #SENSResearchFoundation #MitoSENS #Biotechnology #AgeRelatedDiseases #HealthInnovation #ScientificBreakthroughs #HumanLongevity #Womeninscience #Womeninstem #HealthyAging

🔬 𝐌𝐞𝐞𝐭 𝐭𝐡𝐞 𝐦𝐢𝐧𝐝𝐬 𝐛𝐞𝐡𝐢𝐧𝐝 𝐈𝐧𝐁𝐢𝐨.𝐛𝐞'𝐬 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡: 𝐏𝐡𝐃 𝐒𝐩𝐨𝐭𝐥𝐢𝐠𝐡𝐭 🔬 Join us as we turn our attention to the exceptional work of our PhD students at InBio.be. Today, we're proud to feature Thomas Willems, a dedicated contributor to our research endeavors, exploring new avenues for 𝗜𝗺𝗶𝗻𝗼𝘀𝘂𝗴𝗮𝗿𝘀. These compounds are known for their potential in future medicine for the treatment of various cancers, viral infections and so on. However, current production processes are neither durable nor affordable. Through the metabolic engineering of model organisms 𝗯𝗮𝗸𝗲𝗿'𝘀 𝘆𝗲𝗮𝘀𝘁 𝗮𝗻𝗱 𝗘. 𝗰𝗼𝗹𝗶, Thomas' research aims to develop a sustainable and low-cost production method for these interesting molecules. This way, these natural products' full potential can be unlocked. 💊 Discover more of Thomas Willems’ pioneering research journey and the impact it's making in drug development! https://lnkd.in/eiuBkb-v #Innovation #ResearchExcellence #InBioSpotlight #PhDResearch

As a valuable addition to the London Biotechnology Show, 𝗕𝗶𝗼𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆 𝗮𝗻𝗱 𝗕𝗶𝗼𝗹𝗼𝗴𝗶𝗰𝗮𝗹 𝗦𝗰𝗶𝗲𝗻𝗰𝗲𝘀 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗖𝗼𝘂𝗻𝗰𝗶𝗹 (𝗕𝗕𝗦𝗥𝗖) has joined us as a Supporting Partner. The Biotechnology and Biological Sciences Research Council (BBSRC), part of UK Research and Innovation, is the UK’s major public funder of bioscience research and innovation. Our aim is to further scientific knowledge, promote economic growth, wealth and job creation and improve quality of life in the UK and beyond. BBSRC invested £461 million in world-class bioscience in 2023. We support research and training in universities and strategically supported institutes. BBSRC research and the people we fund are helping society address major challenges including food security, green energy and healthier, longer lives. Our investments underpin important UK economic sectors such as agriculture, food, industrial biotechnology and pharmaceuticals. Book your free visitor pass at https://lnkd.in/geed7HiH #lbs #lbs24 #londonbiotechnologyshow #biotechnology #innovation #bioinformatics #medtech #agriculture #bioengineering #innovation #lifesciences #bioenergy #genetics

Currently, the number of compounds available for human drug development is limited. For this reason (and others), bioprospecting plays a dominant role in the discovery of leads for drug development. In addition, marine resources have become very promising as they are largely undiscovered and can provide chemical novelty and complexity that can be enhanced by scientists. That is where EUREMAP comes in. We aim to harness the existing strengths in marine bioprospecting in Europe and create a new pipeline that aligns and integrates the technical capacities of four major European Research Infrastructures EU-OPENSCREEN, EMBRC - European Marine Biological Resource Centre, EMBL and ELIXIR. Together, we will build a new European transnational service platform for marine natural product discovery and catalyse academic and industrial competitiveness! UiT Norges arktiske universitet | Fundacion MEDINA | Universiteit Gent | Tel Aviv University | Helmholtz Centre for Infection Research | SINTEF | Centre of Marine Sciences (CCMAR) | Consiglio Nazionale delle Ricerche | Sorbonne Université | European Research Executive Agency (REA) | Stazione Zoologica Anton Dohrn | Centre national de la recherche scientifique

Scholars at EMBL have discovered that human medications, which typically inhibit gut bacteria when isolated, have a reduced impact when these bacteria form communities. The study examined how 30 drugs affected 32 species of gut bacteria, revealing that drug-resistant bacteria can protect sensitive species through "cross-protection." This communal defence allows bacteria to thrive despite drug presence. "Up to half of the affected species remained unaffected in the community," noted co-author Sarela Garcia-Santamarina. However, at higher drug concentrations, this protection breaks down, leading to "cross-sensitization," where resistant bacteria become vulnerable. The study opens doors to possibly tailoring prescriptions to minimize drug side effects on the gut microbiome. Read full article on SciTechDaily https://lnkd.in/g9yuRjgi #biomall #biotechnology #science #news #bacteria #research #drugs #communities